Table 3.
KEGG pathway enrichment
| Pathway | # Genes | Estimate | p-value |
|---|---|---|---|
| hsa04350:TGF-beta signaling pathway | 11 | 11.58 | 1.00E-05 |
| hsa03010:Ribosome | 11 | 11.58 | 1.00E-05 |
| hsa04150:mTOR signaling pathway | 8 | 8.42 | 1.04E-04 |
| hsa02010:ABC transporters | 7 | 7.37 | 3.36E-04 |
| hsa04630:Jak-STAT signaling pathway | 9 | 9.47 | 0.00901 |
| hsa04620:Toll-like receptor signaling pathway | 7 | 7.37 | 0.01620 |
| hsa04010:MAPK signaling pathway | 11 | 11.58 | 0.01982 |
| hsa04914:Progesterone-mediated oocyte maturation | 6 | 6.32 | 0.03358 |
| hsa04012:ErbB signaling pathway | 6 | 6.32 | 0.03330 |
| hsa04722:Neurotrophin signaling pathway | 7 | 7.37 | 0.03265 |
| hsa04060:Cytokine-cytokine receptor interaction | 10 | 10.53 | 0.04148 |
Pathways according to KEGG computed as significantly enriched in molecular process 4 of the HGSOCr molecular model. Pathways given in bold are further identified as enriched in the drug mechanism of action model overlap feature set of cisplatin and paclitaxel matching with molecular process 4 members of the HGSOCr molecular model